Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02906917 · ClinicalTrials.gov registry record · Phase 3
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 532
- Enrollment target
NCT02906917 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 532 participants.
The verdict
NCT02906917, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 532 participants
- Enrollment target
Study Summary
Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of treatment intensification.
Interventions
- DRUG Insulin aspart
- DRUG Insulin glargine
- DRUG Insulin degludec/insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2017-12-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02906917
The ClinicalTrials.gov registry entry for NCT02906917 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 532 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Insulin aspart is the first listed.
NCT02906917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02906917 about?
NCT02906917 is a clinical study titled "A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification". Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of treatment intensification.
What is the current status of trial NCT02906917?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 532 participants. The study started on 2016-09-20. Estimated completion is 2017-12-24.
What interventions are being tested in trial NCT02906917?
The interventions under investigation include: Insulin aspart (DRUG), Insulin glargine (DRUG), Insulin degludec/insulin aspart (DRUG).
Who is sponsoring clinical trial NCT02906917?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.